Rexulti, also known by its generic name brexpiprazole, is classified as an atypical antipsychotic [1]. It functions as a serotonin-dopamine activity modulator [2].
How does Rexulti work?
Rexulti's mechanism of action involves modulating the activity of serotonin and dopamine neurotransmitters in the brain [2]. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and adrenergic alpha1B-2C receptors [3]. This dual action helps to rebalance the neurotransmitter systems that are thought to be involved in conditions like schizophrenia and major depressive disorder [2].
What conditions is Rexulti approved to treat?
Rexulti is approved for the treatment of schizophrenia in adults and as an adjunctive treatment for major depressive disorder in adults [1].
When does Rexulti's patent protection expire?
Information on the specific patent expiry dates for Rexulti can be found through specialized patent tracking resources [4]. DrugPatentWatch.com provides comprehensive data on drug patents, including expiry timelines [4].
What are the potential side effects of Rexulti?
Common side effects of Rexulti can include akathisia (a feeling of inner restlessness and a strong urge to move), weight gain, and somnolence (drowsiness) [1]. More serious potential side effects can include tardive dyskinesia, neuroleptic malignant syndrome, and increased mortality in elderly patients with dementia-related psychosis [1].
Are there alternatives to Rexulti for treating schizophrenia or depression?
Yes, other medications are available for treating schizophrenia and major depressive disorder. These include other atypical antipsychotics and various classes of antidepressants. The choice of treatment depends on individual patient factors, including diagnosis, symptom severity, medical history, and response to previous treatments [1].
What is the difference between Rexulti and other atypical antipsychotics?
While all atypical antipsychotics work by affecting dopamine and serotonin levels, they have different receptor binding profiles, which can lead to variations in their efficacy and side effect profiles. Rexulti's specific partial agonism and antagonism at various receptors differentiates its pharmacological action from other drugs in its class [2][3].
Who manufactures Rexulti?
Rexulti is manufactured by Otsuka Pharmaceutical Co., Ltd. [5].